TITLE

Most Pharmaceutical Companies Receive Poor Grades on HIV/AIDS Drug Development Innovation, According to AIDS Treatment Activist Coalition Report Card; Many Companies Get Low Marks in Five Benchmark Treatment Categories; New Drugs Need to Reflect

PUB. DATE
September 2009
SOURCE
Ascribe Newswire: Health;9/10/2009, p1
SOURCE TYPE
Newswire
DOC. TYPE
Article
ABSTRACT
The article reports on the poor grades received by most U.S. pharmaceutical companies on HIV and AIDS drug development innovation. According to AIDS Treatment Activist Coalition Report Card, most companies obtain low marks in five benchmark treatment categories. It indicates that many pharmaceutical companies are not developing innovative, new long-term treatment alternatives that offer improved efficacy, safety and tolerability when taken for decades.
ACCESSION #
44181399

 

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics